



April 24, 2026

Company name: Taiko Pharmaceutical Co., Ltd.
Representative: Takashi Shibata
President and CEO
Securities code: 4574 (TSE Prime Market)
Contact: Toru NakajoVP,
Corporate Division,
Accounting Department
(E-mail: ir@seirogan.co.jp)

Notice regarding Receipt of Dividends from a Consolidated Subsidiary

Taiko Pharmaceutical Co., Ltd. (the "Company") hereby announces that it will receive dividends of surplus from Taiko Pharmaceutical (Asia Pacific) Co., Ltd., a consolidated subsidiary of the Company. As this matter is subject to the filing requirement of an extraordinary report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 12 of the Cabinet Office Ordinance on Disclosure of Corporate Affairs, the Company provides notice as set forth below.

1. Outline of the Dividends

- (1) Name of the consolidated subsidiary: Taiko Pharmaceutical (Asia Pacific) Co., Ltd.
- (2) Amount of dividends: HKD 15 million (approximately JPY 306 million) (HKD 1 = JPY 20.40)
- (3) Date of dividend receipt (planned): May 25, 2026

2. Impact on Financial Results

The total amount of dividends to be received will be recorded as Dividend income in the non-consolidated financial results for FY2026/12. There will be no impact on the consolidated financial results for FY2026/12 as the dividends to be received are from the consolidated subsidiary of the Company.

End